Clinical TrialCrossoverKetaminePlaceboCompleted

Ketamine Infusion for Social Anxiety Disorder

* Social Anxiety Disorder (SAD) is common and causes significant impairment. * First-line treatments for Social Anxiety Disorder are only partially effective. Many SAD patients experience little or inadequate symptom relief with available treatments. * Ketamine is a potent NMDA receptor antagonist. Ketamine represents an agent with a potentially novel mechanism of action for the treatment of anxiety disorders. * Ketamine has demonstrated efficacy in the treatment of psychiatric disorders closely related to Social Anxiety Disorder including Major Depression, Bipolar Depression and possibly Obsessive-Compulsive Disorder. Ketamine represents the possibility to provide rapid symptom relief to patients with SAD and may provide the mechanism for future drug development to treat SAD more rapidly and effectively.

Ask Blossom about this trial
Target Enrollment
18 participants
Study Type
Phase I interventional
Design
Randomized, quadruple Blind

Continue exploring

Continue exploring this trial

Move from the registry record to the most relevant public research context.

Related paper: Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover TrialCompound research: Ketamine

Study Arms & Interventions

Ketamine 35 mg/70 kg

experimental

Intravenous ketamine infusion (0.5 mg/kg over 40 min)

Interventions

  • Ketamine0.5 mg/kg
    via IV• single dose• 1 doses total

    administered over 40 min

Placebo (matched to ketamine 35 mg/70 kg)

placebo

Intravenous normal saline infusion

Interventions

  • Placebo
    via IV• single dose• 1 doses total

    normal saline

Study Protocol, Arms & Participants

Go Pro to access detailed study protocol timelines, treatment arms, dosing schedules, and participant eligibility criteria.

See Pro Plans

Study Details

  • Status
    Completed
  • Phase
    Phase I
  • Type
    interventional
  • Design
    Randomizedquadruple Blind
  • Target Enrollment18 participants
  • Timeline
    Start: 2015-01-02
    End: 2016-09-27
  • Compounds
    KetaminePlacebo

Study Team

Sponsors & Collaborators

Investigators

  • MB
    Michael Bloch

Related Publications

Open AccessindividualPrimary

Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial

This double-blind, placebo-controlled crossover trial (n=18) investigated the effects of intravenous ketamine (35 mg/70 kg) in adults with social anxiety disorder. It finds that ketamine resulted in a significantly greater reduction in anxiety symptoms compared with placebo on clinician-rated measures, although self-reported anxiety scores did not show a significant difference.

Published
Journal
Neuropsychopharmacology
Authors
Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C., Mulqueen, J., Johnson, J. A., Gabriel, D., Reed, M. O., Jakubovski, E., Bloch, M. H.

Recent activity

Your Personal Research Library

Go Pro to save trials, add notes, rate research, and organize custom shelves.

See Pro Plans